404 related articles for article (PubMed ID: 28490565)
1. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
[TBL] [Abstract][Full Text] [Related]
5. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
Kang SM; Yun HM; Sohn M; Lim S
Diabetes Obes Metab; 2023 Jul; 25(7):1922-1931. PubMed ID: 36932823
[TBL] [Abstract][Full Text] [Related]
6. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
Watanabe K; Yamaguchi S; Kosakai Y; Ioji T; Ishihara H
Clin Drug Investig; 2023 Dec; 43(12):927-937. PubMed ID: 37934351
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H; Furusawa S; Nakamura A; Takeuchi J; Nagai S; Yokoyama H; Sakuma I; Taneda S; Kurihara Y; Aoki S; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
BMJ Open; 2022 May; 12(5):e056885. PubMed ID: 35584872
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Wilding JP; Ferrannini E; Fonseca VA; Wilpshaar W; Dhanjal P; Houzer A
Diabetes Obes Metab; 2013 May; 15(5):403-9. PubMed ID: 23163880
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
14. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Kim NH; Lim S; Kwak SH; Moon MK; Moon JS; Lee YH; Cho HC; Lee J; Kim SG
BMJ Open; 2018 Sep; 8(9):e022448. PubMed ID: 30249630
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Cefalu WT; Leiter LA; Yoon KH; Arias P; Niskanen L; Xie J; Balis DA; Canovatchel W; Meininger G
Lancet; 2013 Sep; 382(9896):941-50. PubMed ID: 23850055
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
19. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]